Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing

The essence of precision medicine is to achieve the goal of “individualized treatment” through genotyping of patients and targeted therapy. At present, the pathogenic genes of non-small cell lung cancer (NSCLC) have been studied most thoroughly and targeted therapy based on genotyping has been the m...

Full description

Bibliographic Details
Main Authors: Jingsi Dong, Bingjie Li, Dan Lin, Qinghua Zhou, Depei Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Pharmacology
Subjects:
NSCLC
targeted therapy
immunotherapy
EGFR
PD-L1
ALK
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00230/full
id doaj-a06463d539ec4ce7942b7834c48c2287
record_format Article
spelling doaj-a06463d539ec4ce7942b7834c48c22872020-11-24T22:30:00ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-03-011010.3389/fphar.2019.00230445599Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular TypingJingsi Dong0Bingjie Li1Dan Lin2Qinghua Zhou3Depei Huang4Lung Cancer Center of West China Hospital, Sichuan University, Chengdu, ChinaLung Cancer Center of West China Hospital, Sichuan University, Chengdu, ChinaLung Cancer Center of West China Hospital, Sichuan University, Chengdu, ChinaLung Cancer Center of West China Hospital, Sichuan University, Chengdu, ChinaThe Medical Department, 3D Medicines Inc., Shanghai, ChinaThe essence of precision medicine is to achieve the goal of “individualized treatment” through genotyping of patients and targeted therapy. At present, the pathogenic genes of non-small cell lung cancer (NSCLC) have been studied most thoroughly and targeted therapy based on genotyping has been the most successful. This paper focuses on the precision treatment of NSCLC based on genotyping, comparing gene detection methods and summarize the latest progress of NSCLC immunotherapy.https://www.frontiersin.org/article/10.3389/fphar.2019.00230/fullNSCLCtargeted therapyimmunotherapyEGFRPD-L1ALK
collection DOAJ
language English
format Article
sources DOAJ
author Jingsi Dong
Bingjie Li
Dan Lin
Qinghua Zhou
Depei Huang
spellingShingle Jingsi Dong
Bingjie Li
Dan Lin
Qinghua Zhou
Depei Huang
Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
Frontiers in Pharmacology
NSCLC
targeted therapy
immunotherapy
EGFR
PD-L1
ALK
author_facet Jingsi Dong
Bingjie Li
Dan Lin
Qinghua Zhou
Depei Huang
author_sort Jingsi Dong
title Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
title_short Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
title_full Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
title_fullStr Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
title_full_unstemmed Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
title_sort advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2019-03-01
description The essence of precision medicine is to achieve the goal of “individualized treatment” through genotyping of patients and targeted therapy. At present, the pathogenic genes of non-small cell lung cancer (NSCLC) have been studied most thoroughly and targeted therapy based on genotyping has been the most successful. This paper focuses on the precision treatment of NSCLC based on genotyping, comparing gene detection methods and summarize the latest progress of NSCLC immunotherapy.
topic NSCLC
targeted therapy
immunotherapy
EGFR
PD-L1
ALK
url https://www.frontiersin.org/article/10.3389/fphar.2019.00230/full
work_keys_str_mv AT jingsidong advancesintargetedtherapyandimmunotherapyfornonsmallcelllungcancerbasedonaccuratemoleculartyping
AT bingjieli advancesintargetedtherapyandimmunotherapyfornonsmallcelllungcancerbasedonaccuratemoleculartyping
AT danlin advancesintargetedtherapyandimmunotherapyfornonsmallcelllungcancerbasedonaccuratemoleculartyping
AT qinghuazhou advancesintargetedtherapyandimmunotherapyfornonsmallcelllungcancerbasedonaccuratemoleculartyping
AT depeihuang advancesintargetedtherapyandimmunotherapyfornonsmallcelllungcancerbasedonaccuratemoleculartyping
_version_ 1725742303093456896

Similar Items